This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency

This study has been terminated.
(The trial was prematurely terminated due to low recruitment)
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: October 1, 2012
Last updated: February 23, 2017
Last verified: February 2017
This trial is conducted in Europe. The aim of this trial is to investigate the effect of growth hormone on left ventricle morphology and function (systolic and diastolic).

Condition Intervention Phase
Growth Hormone Disorder Adult Growth Hormone Deficiency Drug: somatropin Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Left Ventricular systolic function
  • Left Ventricular diastolic function

Secondary Outcome Measures:
  • Body composition
  • Fasting glucose
  • HbA1c (glycosylated haemoglobin)
  • Oral glucose tolerance test (OGTT)

Enrollment: 7
Actual Study Start Date: May 16, 2001
Study Completion Date: November 18, 2002
Primary Completion Date: November 18, 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Somatropin Drug: somatropin
Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily


Ages Eligible for Study:   12 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult growth hormone deficiency
  • At least 2 years without growth hormone treatment

Exclusion Criteria:

  • Supine blood pressure above 160 mmHg systolic or above 100 mmHg diastolic
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01698944

Novo Nordisk Investigational Site
Athens, Greece, GR-11527
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S Identifier: NCT01698944     History of Changes
Other Study ID Numbers: GHDADULT-1112
Study First Received: October 1, 2012
Last Updated: February 23, 2017

Additional relevant MeSH terms:
Endocrine System Diseases
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 21, 2017